肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

JCEM：除了降钙素，它也可以评估甲状腺髓样癌预后？

2017-08-08 xuyihan MedSci原创

循环游离DNA甲状腺髓样癌预后
关注

众所周知降钙素是预测甲状腺髓样癌（MCT）预后的重要指标，然而由于其需要在较长时间内多次测量，使其成为了评估预后不完美的生物标记物。单循环游离DNA（cfDNA）已经显示出对多种实体肿瘤有效的预后标记物。Gilbert J. Cote等人对cfDNA在MCT中的预后评估价值进行了研究。

众所周知降钙素是预测甲状腺髓样癌（MCT）预后的重要指标，然而由于其需要在较长时间内多次测量，使其成为了评估预后不完美的生物标记物。单循环游离DNA（cfDNA）已经显示出对多种实体肿瘤有效的预后标记物。Gilbert J. Cote等人对cfDNA在MCT中的预后评估价值进行了研究。

该研究想验证有RET M918T突变的cfDNA能在患有严重MTC、肿瘤有M918T突变的患者的血清样本中检测到，而且能够比降钙素更可靠的预计总生存期这一假设。研究纳入已确诊MTC的散发患者，血清降钙素大于100 pg/ml，且肿瘤组织活检结果提示有RET M918T突变。共纳入75例患者，其中50例通过组织活检证明有RET M918T突变，再通过PCR测定有RET M918T突变的cfDNA水平。

研究结果显示在50例活检阳性的患者中有16例（32%）检测到RET M918T cfDNA。检测到RET M918T cfDNA与总生存率差显着相关，且较降钙素倍增时间更准确地预测更坏的结果。

由上述研究可见液体活检能够检测到患者血清中的RET M918T突变，特异性高但敏感性低。在有RET M918T突变的患者中，循环肿瘤DNA等位基因的碎片对总生存期具有预后评估价值，也许能在检测治疗反应中发挥作用。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1821999, encodeId=16b6182199929, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Sep 15 06:06:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063030, encodeId=3291206303087, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Aug 08 20:06:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777648, encodeId=a3f81e7764827, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Jan 26 16:06:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232166, encodeId=3958232166cb, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Aug 10 13:13:04 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-09-15 Boyinsh

    #髓样癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1821999, encodeId=16b6182199929, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Sep 15 06:06:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063030, encodeId=3291206303087, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Aug 08 20:06:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777648, encodeId=a3f81e7764827, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Jan 26 16:06:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232166, encodeId=3958232166cb, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Aug 10 13:13:04 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-08 achengzhao

    #JCE#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1821999, encodeId=16b6182199929, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Sep 15 06:06:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063030, encodeId=3291206303087, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Aug 08 20:06:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777648, encodeId=a3f81e7764827, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Jan 26 16:06:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232166, encodeId=3958232166cb, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Aug 10 13:13:04 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2018-01-26 smallant2015

    #JCEM#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1821999, encodeId=16b6182199929, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Sep 15 06:06:00 CST 2017, time=2017-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2063030, encodeId=3291206303087, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Tue Aug 08 20:06:00 CST 2017, time=2017-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777648, encodeId=a3f81e7764827, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Fri Jan 26 16:06:00 CST 2018, time=2018-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=232166, encodeId=3958232166cb, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Aug 10 13:13:04 CST 2017, time=2017-08-10, status=1, ipAttribution=)]
    2017-08-10 luominglian113

    学习了，谢谢分享

    0